Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.50 |
| ▸ | ADH1C | P00326 | 1/20 | 0.50 |
| ▸ | ADH1A | P07327 | 1/20 | 0.50 |
| ▸ | ADH7 | P40394 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536584 | 0.86 | ADH1B (0.47) | ADH1BADH1CADH1AADH7EPHX2 | |
| SCHEMBL3889241 | 0.83 | EPHX2 (0.49) | EPHX2NR1H4SCN8AHTR2C | |
| SCHEMBL8348550 | 0.83 | SCN8A (0.55) | EPHX2NR1H4SCN8ABCHEACHE | |
| SCHEMBL5540697 | 0.82 | ADH1B (0.41) | ADH1BADH1CADH1AADH7EPHX2 | |
| Hydrochloric Acid SCHEMBL6122751 | 0.81 | SCN8A (0.54) | EPHX2NR1H4SCN8ABCHEACHE | |
| SCHEMBL5541752 | 0.80 | SLC6A5 (0.46) | EPHX2NR1H4SCN8AHDAC3HDAC1 | |
| SCHEMBL3128866 | 0.80 | GAA (0.49) | EPHX2NR1H4SCN8AKDM1APLA2G1B | |
| SCHEMBL3891414 | 0.80 | CHRM2 (0.53) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL23655798 | 0.80 | HDAC1 (0.43) | EPHX2NR1H4SCN8ABCHEACHE | |
| SCHEMBL5537500 | 0.79 | SLC6A5 (0.47) | EPHX2NR1H4SCN8AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4822903-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-04-18 | — | — | US | disclosed |
| US-4504595-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-03-12 | — | — | US | disclosed |
| EP-0067080-B1 | N-FLUORINATED BENZYL AMIDES AND PROCESS FOR THEIR PREPARATION | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-11-21 | — | — | EP | disclosed |
| US-4438042-A | FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | disclosed |
| US-4436669-A | CYANATION, DECARBONYLATION, ACID CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-13 | — | — | US | disclosed |
| EP-0067080-A1 | N-fluorinated benzyl amides and process for their preparation | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ADH1B 281/4885ADH1C 285/4885ADH1A 494/4885 |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | ADH1B 3539/4885ADH1C 4522/4885ADH1A 4681/4885 |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | ADH1B 705/4885ADH1C 297/4885ADH1A 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.